Melinda L Telli

10PUBLICATIONS
78CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 20, 2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

|Dec 17, 2025
Multiscale profiling of tyrosine kinase inhibitor cardiotoxicity reveals mechanosensitive ion channel PIEZO1 as cardioprotective.

Amit Manhas, Yu Liu, Chikage Noishiki

|Jul 14, 2025
A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression.

Yan Zhao, Tina Andoh, Fatima Charles

|Jun 04, 2025
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Elizabeth A Mittendorf, Zoe June Assaf, Nadia Harbeck

|Jan 21, 2025
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.

Fatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu

|Jun 13, 2024
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.

Melinda L Telli, Jennifer K Litton, J Thaddeus Beck

Pageof 2

Frequent Collaborators

2 joint publications

Joshua J Gruber

2 joint publications

Julia D Ransohoff

2 joint publications

Allison W Kurian

2 joint publications

Nadia Harbeck